| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial L Fehrenbacher, A Spira, M Ballinger, M Kowanetz, J Vansteenkiste, ... The Lancet 387 (10030), 1837-1846, 2016 | 2851 | 2016 |
| Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC RS Herbst, G Giaccone, F de Marinis, N Reinmuth, A Vergnenegre, ... New England Journal of Medicine 383 (14), 1328-1339, 2020 | 1175 | 2020 |
| Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab DR Gandara, SM Paul, M Kowanetz, E Schleifman, W Zou, Y Li, ... Nature medicine 24 (9), 1441-1448, 2018 | 1082 | 2018 |
| Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study DF McDermott, JA Sosman, M Sznol, C Massard, MS Gordon, O Hamid, ... Journal of Clinical Oncology 34 (8), 833-842, 2016 | 581 | 2016 |
| IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC MA Socinski, M Nishio, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ... Journal of Thoracic Oncology 16 (11), 1909-1924, 2021 | 274 | 2021 |
| Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) M Kowanetz, W Zou, SN Gettinger, H Koeppen, M Kockx, P Schmid, ... Proceedings of the National Academy of Sciences 115 (43), E10119-E10126, 2018 | 218 | 2018 |
| Modeling quantitative trait loci and interpretation of models ZB Zeng, T Wang, W Zou Genetics 169 (3), 1711-1725, 2005 | 191 | 2005 |
| Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer NS Patil, BY Nabet, S Müller, H Koeppen, W Zou, J Giltnane, A Au-Yeung, ... Cancer cell 40 (3), 289-300. e4, 2022 | 169 | 2022 |
| OA20. 01 tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients M Kowanetz, W Zou, D Shames, C Cummings, N Rizvi, A Spira, ... Journal of Thoracic Oncology 12 (1), S321-S322, 2017 | 103 | 2017 |
| Blood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) DR Gandara, M Kowanetz, TSK Mok, A Rittmeyer, L Fehrenbacher, ... Annals of Oncology 28, v460, 2017 | 89 | 2017 |
| Blood-based biomarkers for cancer immunotherapy: tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) DR Gandara, M Kowanetz, TSK Mok, A Rittmeyer, L Fehrenbacher, ... Annals of Oncology 28, v460, 2017 | 89 | 2017 |
| Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade R Banchereau, AS Chitre, A Scherl, TD Wu, NS Patil, P de Almeida, ... Journal for ImmunoTherapy of Cancer 9 (4), 2021 | 84 | 2021 |
| Gain and Loss of Function of P2X7 Receptors: Mechanisms, Pharmacology and Relevance to Diabetic Neuropathic Pain D Ursu, P Ebert, E Langron, C Ruble, L Munsie, W Zou, B Fijal, YW Qian, ... Molecular pain 10, 1744-8069-10-37, 2014 | 80 | 2014 |
| Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the … HJ West, M McCleland, F Cappuzzo, M Reck, TSK Mok, RM Jotte, ... Journal for Immunotherapy of Cancer 10 (2), 2022 | 72 | 2022 |
| Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma NS Patil, L Righi, H Koeppen, W Zou, S Izzo, F Grosso, R Libener, ... Journal of Thoracic Oncology 13 (1), 124-133, 2018 | 63 | 2018 |
| Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC M Kowanetz, W Zou, DS Shames, C Cummings, N Rizvi, AI Spira, ... Annals of Oncology 27, vi23, 2016 | 60 | 2016 |
| Speed-mapping quantitative trait loci using microarrays CQ Lai, J Leips, W Zou, JF Roberts, KR Wollenberg, LD Parnell, ZB Zeng, ... Nature methods 4 (10), 839-841, 2007 | 54 | 2007 |
| MA 05.09 Pre-existing immunity measured by teff gene expression in tumor tissue is associated with atezolizumad efficacy in NSCLC M Kowanetz, W Zou, M McCleland, DR Gandara, S Gadgeel, A Rittmeyer, ... Journal of Thoracic Oncology 12 (11), S1817-S1818, 2017 | 42 | 2017 |
| ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy W Zou, SJ Yaung, F Fuhlbrück, M Ballinger, E Peters, JF Palma, ... JCO Precision Oncology 5, 827-838, 2021 | 38 | 2021 |
| 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA … C Zhou, MD Thakur, MK Srivastava, W Zou, H Xu, M Ballinger, E Felip, ... Annals of Oncology 32, S1374, 2021 | 37 | 2021 |
